We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Toripalimab-Induced Dermatomyositis in a Patient with Metastatic Melanoma.
- Authors
Lin, Jingrong; Xue, Minmin; Gao, Mingyang; Yu, Pu; Han, Shixin
- Abstract
Toripalimab is a monoclonal antibody targeting programmed cell death protein 1 (PD-1). It has recently been approved as an immune checkpoint inhibitor in second-line therapies in patients with unresectable or metastatic melanoma; however, it may be associated with various immune-related adverse events (irAEs). Here we report a case of toripalimab-induced dermatomyositis in a patient receiving treatment for metastatic melanoma. The symptoms were relieved by discontinuing toripalimab and administering once-daily intravenous methylprednisolone 1 mg/kg. We suggest that this case serves a warning to clinicians of the need to be aware of the possiblilty of toripalimab-induced dermatomyositis. Early recognition and treatment may prevent progression and improve prognosis of this irAE.
- Subjects
IMMUNE checkpoint inhibitors; MELANOMA; PROGRAMMED cell death 1 receptors; SYMPTOMS; MONOCLONAL antibodies
- Publication
Dermatology & Therapy, 2020, Vol 10, Issue 4, p863
- ISSN
2193-8210
- Publication type
Article
- DOI
10.1007/s13555-020-00396-6